Oragenics Inc Dossier - Source-backed chat

Oragenics Inc

OGENNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.14

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.48Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.1M

Enterprise Value −$1.8M

Shares Outstanding 4.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Oragenics Inc. is a clinical-stage biotechnology company focused on developing brain-targeted intranasal therapeutics, primarily its lead candidate ONP-002 for mild traumatic brain injury (concussion). While the company has successfully transitioned its clinical operations to Australia—initiating site activation and dosing its first patients in a Phase IIa trial—it faces severe financial constraints. With only $6.1 million in cash as of March 31, 2026, and a runway extending only through the end of 2026, the company's auditor has issued a going concern warning. Investors should maintain a Hold stance, balancing the high-potential, first-in-class nature of its concussion therapy against imminent dilution and financing risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Clinical trial enrollment in Australia faces delays due to institutional bottlenecks. The FDA requests additional preclinical or manufacturing data during the Type C meeting, pushing back the IND timeline. Unable to secure favorable terms, the company is forced to execute highly dilutive equity financing at a steep discount, or faces a liquidity crisis as cash runs out by late 2026.

Base CaseCentral scenario

The Phase IIa trial of ONP-002 in Australia progresses steadily with positive safety and early efficacy readouts by late 2026. The company successfully submits its Type C meeting request and files its U.S. IND by year-end. To fund operations into 2027, Oragenics executes a dilutive capital raise or utilizes its ATM facility, which temporarily depresses the stock price but resolves immediate going concern issues.

Bull CaseUpside scenario

Oragenics offers a high-optionality play on the first potential FDA-approved pharmacological treatment for concussions (ONP-002), targeting a massive $9 billion global market with zero direct competition. Its proprietary direct-to-brain intranasal delivery platform bypasses the blood-brain barrier and holds standalone licensing potential across multiple CNS indications.

Scenarios reflect our research view at the research date.

Key Investment Merits

First-in-class intranasal neurosteroid (ONP-002) targeting a massive, completely unserved $9 billion global concussion market with no currently approved pharmacological treatments.
Proprietary intranasal delivery device bypasses the blood-brain barrier, offering rapid, non-invasive therapeutic delivery directly to the brain.
Regained full compliance with NYSE American listing standards in late 2025, restoring institutional viability.

Key Investment Risks

Severe going concern risk with a cash runway of $6.1 million only lasting until December 31, 2026, necessitating near-term dilutive capital raises.
High regulatory hurdles and clinical execution risks associated with transitioning trials from Australia to the United States.
Significant potential dilution from outstanding Series F and Series H preferred stock and associated warrants.

Thesis Invalidation Triggers

Failure to submit the FDA Type C meeting request or receive positive guidance in 2026.
Inability to secure additional financing before Q4 2026, leading to a suspension of clinical operations.
Safety signals or serious adverse events reported in the ongoing Australian Phase IIa trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.